Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Sep;41(9):1867–1870. doi: 10.1128/aac.41.9.1867

Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin.

M A Visalli 1, M R Jacobs 1, P C Appelbaum 1
PMCID: PMC164026  PMID: 9303375

Abstract

Agar dilution with incubation in air and CO2 was used to determine the MICs of erythromycin, dirithromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin for 79 penicillin-susceptible, 72 penicillin-intermediate, and 74 penicillin-resistant pneumococci (158 erythromycin-susceptible and 67 erythromycin-resistant pneumococci). MICs obtained in air were usually 1 to 3 dilutions lower than those obtained in CO2. In air, the respective MICs at which 50% (MIC50s) and 90% (MIC90s) of penicillin-susceptible, -intermediate, and -resistant strains are inhibited were as follows: erythromycin, 0.016 and 0.5, 0.03 and > 64, and 2 and > 64 microg/ml; dirithromycin, 0.03 and 0.5, 0.06 and > 64, and 8 and > 64 microg/ml; azithromycin, 0.03 and 0.5, 0.06 and > 64, and 2 and > 64 microg/ml; clarithromycin, 0.016 and 0.06, 0.03 and > 64, and 2 and > 64 microg/ml; roxithromycin, 0.06 and 2, 0.06 and > 64, and 2 and > 64 microg/ml; and clindamycin, 0.03 and 0.06, 0.06 and > 64, and 0.06 and > 64 microg/ml. The MICs of erythromycin, azithromycin, and dirithromycin were very similar; however, clarithromycin MICs were generally 1 to 2 dilutions lower and roxithromycin MICs were 1 to 2 dilutions higher than those of the other compounds tested. Strains resistant to one macrolide were resistant to all macrolides; however, not all macrolide-resistant strains were resistant to clindamycin, and 32 macrolide-resistant (MICs, > or = 28 microg/ml), clindamycin-susceptible (MICs, < or = 0.25 microg/ml) strains were encountered. Time-kill testing of six strains showed similar killing kinetics for all compounds, with 99.9% killing of all strains observed with the compounds only at or above the MIC after 24 h.

Full Text

The Full Text of this article is available as a PDF (193.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum P. C. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis. 1992 Jul;15(1):77–83. doi: 10.1093/clinids/15.1.77. [DOI] [PubMed] [Google Scholar]
  2. Barry A. L., Pfaller M. A., Fuchs P. C. Dirithromycin disc susceptibility tests: interpretative criteria and quality control parameters. J Antimicrob Chemother. 1993 Mar;31 (Suppl 100):27–37. doi: 10.1093/jac/31.suppl_c.27. [DOI] [PubMed] [Google Scholar]
  3. Barry A. L., Pfaller M. A., Fuchs P. C., Packer R. R. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993. Antimicrob Agents Chemother. 1994 Oct;38(10):2419–2425. doi: 10.1128/aac.38.10.2419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bauernfeind A. In-vitro activity of dirithromycin in comparison with other new and established macrolides. J Antimicrob Chemother. 1993 Mar;31 (Suppl 100):39–49. doi: 10.1093/jac/31.suppl_c.39. [DOI] [PubMed] [Google Scholar]
  5. Bergogne-Bérézin E. Tissue distribution of dirithromycin: comparison with erythromycin. J Antimicrob Chemother. 1993 Mar;31 (Suppl 100):77–87. doi: 10.1093/jac/31.suppl_c.77. [DOI] [PubMed] [Google Scholar]
  6. Block S. L., Harrison C. J., Hedrick J. A., Tyler R. D., Smith R. A., Keegan E., Chartrand S. A. Penicillin-resistant Streptococcus pneumoniae in acute otitis media: risk factors, susceptibility patterns and antimicrobial management. Pediatr Infect Dis J. 1995 Sep;14(9):751–759. doi: 10.1097/00006454-199509000-00005. [DOI] [PubMed] [Google Scholar]
  7. Breiman R. F., Butler J. C., Tenover F. C., Elliott J. A., Facklam R. R. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 1994 Jun 15;271(23):1831–1835. [PubMed] [Google Scholar]
  8. Counter F. T., Ensminger P. W., Preston D. A., Wu C. Y., Greene J. M., Felty-Duckworth A. M., Paschal J. W., Kirst H. A. Synthesis and antimicrobial evaluation of dirithromycin (AS-E 136; LY237216), a new macrolide antibiotic derived from erythromycin. Antimicrob Agents Chemother. 1991 Jun;35(6):1116–1126. doi: 10.1128/aac.35.6.1116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Doern G. V., Brueggemann A., Holley H. P., Jr, Rauch A. M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996 May;40(5):1208–1213. doi: 10.1128/aac.40.5.1208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ednie L. M., Visalli M. A., Jacobs M. R., Appelbaum P. C. Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. Antimicrob Agents Chemother. 1996 Aug;40(8):1950–1952. doi: 10.1128/aac.40.8.1950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fasola E. L., Bajaksouzian S., Appelbaum P. C., Jacobs M. R. Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods. Antimicrob Agents Chemother. 1997 Jan;41(1):129–134. doi: 10.1128/aac.41.1.129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Friedland I. R., McCracken G. H., Jr Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med. 1994 Aug 11;331(6):377–382. doi: 10.1056/NEJM199408113310607. [DOI] [PubMed] [Google Scholar]
  13. Jacobs M. R. Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae. Clin Infect Dis. 1992 Jul;15(1):119–127. doi: 10.1093/clinids/15.1.119. [DOI] [PubMed] [Google Scholar]
  14. Mason E. O., Jr, Kaplan S. L., Lamberth L. B., Tillman J. Increased rate of isolation of penicillin-resistant Streptococcus pneumoniae in a children's hospital and in vitro susceptibilities to antibiotics of potential therapeutic use. Antimicrob Agents Chemother. 1992 Aug;36(8):1703–1707. doi: 10.1128/aac.36.8.1703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Muñoz R., Coffey T. J., Daniels M., Dowson C. G., Laible G., Casal J., Hakenbeck R., Jacobs M., Musser J. M., Spratt B. G. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J Infect Dis. 1991 Aug;164(2):302–306. doi: 10.1093/infdis/164.2.302. [DOI] [PubMed] [Google Scholar]
  16. Nelson C. T., Mason E. O., Jr, Kaplan S. L. Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment. Pediatr Infect Dis J. 1994 Jul;13(7):585–589. doi: 10.1097/00006454-199407000-00001. [DOI] [PubMed] [Google Scholar]
  17. Pankuch G. A., Jacobs M. R., Appelbaum P. C. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob Agents Chemother. 1994 Sep;38(9):2065–2072. doi: 10.1128/aac.38.9.2065. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES